← Leaderboards
Kalipada Pahan
Jesse Brown Va Medical Center
$13,581,878
Attributed
$13,581,878
Total exposure
17
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,581,878 · 12
VA$0 · 5
By mechanism
R01$11,033,352 · 5
R21$2,474,797 · 6
R03$73,729 · 1
I01$0 · 4
IK6$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelBrainAlzheimer&AposMyelinAstrocytesMultiple SclerosisDemyelinationsEffective TherapyBindingMicrogliaGenesInflammationLigandsNeurodegenerative DisordersOligodendrogliaPeroxisome Proliferator-Activated ReceptorsLinkDemyelinating DiseasesRemyelinationPharmaceutical PreparationsBaseExperimental Autoimmune EncephalomyelitisApplications GrantsS Disease
Grant awards (72)
Remyelination by intranasal TIDM peptide$0
I01 · FY2025 · VA · contact PI
BLR&D Research Career Scientist Application$0
IK6 · FY2025 · VA · contact PI
Muscle building supplement HMB for remyelination$384,650
R01 · FY2024 · AT · contact PI
Cinnamon and traumatic brain injury$0
I01 · FY2024 · VA · contact PI
BLR&D Research Career Scientist Application$0
IK6 · FY2024 · VA · contact PI
Remyelination by intranasal TIDM peptide$0
I01 · FY2024 · VA · contact PI
Muscle building supplement HMB for remyelination$392,500
R01 · FY2023 · AT · contact PI
Cinnamon and traumatic brain injury$0
I01 · FY2023 · VA · contact PI
Remyelination by intranasal TIDM peptide$0
I01 · FY2023 · VA · contact PI
BLR&D Research Career Scientist Application$0
IK6 · FY2023 · VA · contact PI
Muscle building supplement HMB for remyelination$392,500
R01 · FY2022 · AT · contact PI
Muscle building supplement HMB for remyelination$392,500
R01 · FY2022 · AT · contact PI
Cinnamon and traumatic brain injury$0
I01 · FY2022 · VA · contact PI
BLR&D Research Career Scientist Application$0
IK6 · FY2022 · VA · contact PI
Muscle building supplement HMB for remyelination$719,572
R01 · FY2021 · AT · contact PI
Intranasal TIDM peptide for tauopathy$157,000
R21 · FY2021 · AG · contact PI
Muscle building supplement HMB for remyelination$65,428
R01 · FY2021 · AT · contact PI
BLR&D Research Career Scientist Application$0
IK6 · FY2021 · VA · contact PI
Cinnamon and traumatic brain injury$0
I01 · FY2021 · VA · contact PI
Muscle building supplement HMB for remyelination$392,500
R01 · FY2020 · AT · contact PI
Intranasal TIDM peptide for tauopathy$392,500
R21 · FY2020 · AG · contact PI
Characterizing novel hippocampal drugs for Alzheimer's disease$387,500
R01 · FY2020 · AG · contact PI
Cinnamon and traumatic brain injury$0
I01 · FY2020 · VA · contact PI
Cinnamon and its metabolite sodium benzoate in Parkinsonism$0
I01 · FY2020 · VA · contact PI
BLR&D Research Career Scientist Application$0
IK6 · FY2020 · VA · contact PI
Characterizing novel hippocampal drugs for Alzheimer's disease$387,500
R01 · FY2019 · AG · contact PI
TLR2-interacting domain of MyD88 peptide for alpha-synucleinopathy$196,250
R21 · FY2019 · NS · contact PI
Characterizing novel hippocampal drugs for Alzheimer's disease$157,000
R01 · FY2019 · AG · contact PI
Cinnamon and its metabolite sodium benzoate in Parkinsonism$0
I01 · FY2019 · VA · contact PI
Characterizing novel hippocampal drugs for Alzheimer's disease$387,500
R01 · FY2018 · AG · contact PI
TLR2-interacting domain of MyD88 peptide for alpha-synucleinopathy$196,250
R21 · FY2018 · NS · contact PI
Cinnamon and its metabolite sodium benzoate in Parkinsonism$0
I01 · FY2018 · VA · contact PI
Characterizing novel hippocampal drugs for Alzheimer's disease$387,500
R01 · FY2017 · AG · contact PI
RANTES and Eotaxin: New players in PD progression$334,688
R01 · FY2017 · NS · contact PI
Identifying novel PPAR? ligands from cerebellum$193,750
R21 · FY2017 · NS · contact PI
Cinnamon and its metabolite sodium benzoate in Parkinsonism$0
I01 · FY2017 · VA · contact PI
Characterizing novel hippocampal drugs for Alzheimer's disease$387,500
R01 · FY2016 · AG · contact PI
RANTES and Eotaxin: New players in PD progression$334,688
R01 · FY2016 · NS · contact PI
Identifying novel PPARÃ ligands from cerebellum$193,750
R21 · FY2016 · NS · contact PI
Cinnamon and its metabolite sodium benzoate in Parkinsonism$0
I01 · FY2016 · VA · contact PI
Aspirin, PPAR and EAE$0
I01 · FY2016 · VA · contact PI
Cinnamon, CNTF and EAE$363,750
R01 · FY2015 · AT · contact PI
RANTES and Eotaxin: New players in PD progression$334,688
R01 · FY2015 · NS · contact PI
Aspirin, PPAR and EAE$0
I01 · FY2015 · VA · contact PI
Cinnamon, CNTF and EAE$363,750
R01 · FY2014 · AT · contact PI
RANTES and Eotaxin: New players in PD progression$331,340
R01 · FY2014 · NS · contact PI
Aspirin, PPAR and EAE$0
I01 · FY2014 · VA · contact PI
Cinnamon, CNTF and EAE$363,750
R01 · FY2013 · AT · contact PI
RANTES and Eotaxin: New players in PD progression$334,688
R01 · FY2013 · NS · contact PI
Aspirin, PPAR and EAE$0
I01 · FY2013 · VA · contact PI
Cinnamon, CNTF and EAE$371,250
R01 · FY2012 · AT · contact PI
Cinnamon, CNTF and EAE$375,000
R01 · FY2011 · AT · contact PI
Castration of male mice: An unexpected way to model PD pathologies$183,750
R21 · FY2011 · NS · contact PI
NEMO-binding domain peptide in a monkey model of PD$147,000
R21 · FY2011 · NS · contact PI
NEMO-binding domain peptide in a monkey model of PD$262,500
R21 · FY2010 · NS · contact PI
Castration of male mice: An unexpected way to model PD pathologies$225,000
R21 · FY2010 · NS · contact PI
Activation of NF-kB in glial cells and CNS of EAE$292,063
R01 · FY2009 · NS · contact PI
Activation of NF-kB in glial cells and CNS of EAE$161,954
R01 · FY2009 · NS · contact PI
Activation of NF-kB in glial cells and CNS of EAE$292,063
R01 · FY2008 · NS · contact PI
Activation of NF-kB in glial cells and CNS of EAE$292,063
R01 · FY2007 · NS · contact PI
Statin and Phenylacetate in MPTP Mouse Model$161,672
R21 · FY2007 · NS · contact PI
Activation of NF-kB in glial cells and CNS of EAE$224,267
R01 · FY2006 · NS · contact PI
Statin and Phenylacetate in MPTP Mouse Model$90,753
R21 · FY2006 · NS · contact PI
Statin and Phenylacetate in MPTP Mouse Model$74,622
R21 · FY2006 · NS · contact PI
Activation of NF-kB in glial cells and CNS of EAE$74,488
R01 · FY2006 · NS · contact PI
Activation of NF-kB in glial cells and CNS of EAE$305,944
R01 · FY2005 · NS
ACTIVATION OF NF-KB IN GLIAL CELLS AND CNS OF EAE$263,470
R01 · FY2004 · NS
ACTIVATION OF NF-KB IN GLIAL CELLS AND CNS OF EAE$254,947
R01 · FY2003 · NS
ACTIVATION OF NF-KB IN GLIAL CELLS AND CNS OF EAE$14,466
R01 · FY2003 · NS
ACTIVATION OF NF-KB IN GLIAL CELLS AND CNS OF EAE$257,760
R01 · FY2002 · NS
ACTIVATION OF NF-KB IN GLIAL CELLS AND CNS OF EAE$258,125
R01 · FY2001 · NS
Amyloid-Beta-induced ceramide production in neurons$73,729
R03 · FY2001 · AG